1719 results about "Rhamnose" patented technology

The invention discloses a quintuple bacterium for conditioning and improving diarrhea, constipation and irritable bowel syndrome. The quintuple bacteria comprise lactobacillus reuteri HBM11-69, pediococcus pentosaceus MPL5, lactobacillus plantarum La-10, lactobacillus rhamnosus HBM11-35 and lactobacillus casei C7-2 bacteria, and the lactobacillus rhamnosus HBM11-35, the pediococcus pentosaceus MPL5, the lactobacillus plantarum La-10, the lactobacillus rhamnosus HBM11-35 and the lactobacillus The strain is found by a Lin Junjunch Teaching Team of South China Agricultural University. The probiotic composition disclosed by the invention is mutually matched and has a synergistic effect, and the intestinal flora structure balance can be effectively recovered by improving the small intestine propulsion rate, reducing the diarrhea frequency and the like. No matter in a viable or inactivated state, the traditional Chinese medicine composition has a relatively good improvement effect on gastrointestinal discomfort such as constipation and irritable bowel syndrome. The quintuplet compound probiotics are high in safety, do not cause adverse reactions such as electrolyte imbalance and can be used for preparing medicines or health foods or foods.

The invention relates to the technical field of biological medicines, and discloses a high-activity lactobacillus rhamnosus probiotic microcapsule, which comprises the following components in parts by weight: lactobacillus rhamnosus: each gram of formula contains 1010 CFU; bifidobacterium: each gram of the formula contains 109 CFU; 10% to 20% of sodium alginate; 5%-15% of chitosan; 3%-8% of hydroxypropyl methyl cellulose; 3%-7% of pectin; 5% to 10% of fructo-oligosaccharide; 5%-10% of inulin; 0.1%-0.5% of vitamin C; and 0.1%-0.3% of vitamin E. Through double-layer and three-layer embedding technologies (such as compound use of sodium alginate and chitosan and compound use of pectin and gelatin), the tolerance of the probiotics in gastric acid and bile environments is remarkably improved, the probiotics are effectively protected through a multi-layer embedding structure, the survival rate of the probiotics in the gastric environment reaches up to 90%, and the release rate in the small intestine exceeds 75%.

The invention relates to the technical field of biological pharmacy, and discloses a probiotic microcapsule with a function of improving intestinal microecology, which comprises the following components in percentage by weight: lactobacillus rhamnosus: each gram of formula contains 1010 CFU of lactobacillus rhamnosus; lactobacillus acidophilus: each gram of the formula contains 109 CFU; clostridium butyricum: each gram of the formula contains 108 CFU; 5%-8% of a nano sodium alginate-chitosan compound; 3%-5% of peptide nanoparticles; 2%-4% of a natural polymer intelligent response film; 3%-6% of arabinoxylan oligosaccharide; 4%-7% of resistant dextran; 2%-4% of lentinan; and 0.1%-0.3% of resveratrol. Through a double-layer or three-layer embedding technology of the nano sodium alginate-chitosan compound and the intelligent response polymer film, the tolerance of the probiotics in gastric acid and cholate environments is remarkably enhanced, and targeted release of the probiotics in small intestines and colon is ensured.

The invention provides a high-temperature-resistant and high-salt-resistant nano imbibition agent as well as a preparation method and application thereof. The high-temperature-resistant and high-salt-resistant nano imbibition agent is prepared from amination modified mesoporous silica nanoparticles, nano cellulose, rhamnolipid, an anionic surfactant, citrate modified sodium zirconium phosphate, polyethylene glycol-b-polycaprolactone and a sulfydryl-carboxyl imidazoline derivative, therefore, the composite carrier formed by the aminated mesoporous silica nanoparticles and the nanocellulose has high mechanical strength and uniform dispersity, the oil-water interfacial tension is reduced through the synergistic effect of the rhamnolipid and the anionic surfactant, and the crude oil stripping efficiency is remarkably improved; the citrate modified sodium zirconium phosphate enables the salt resistance of the system to be greatly improved, and in a high-temperature and high-salt oil reservoir environment, the nano imbibition agent can remarkably improve the crude oil recovery rate and reduce the injection pressure and dosage; meanwhile, good adsorption resistance is achieved, and reservoir blockage is prevented; in addition, low-toxicity corrosion inhibition components protect equipment, and the service life of an oil well is prolonged.

The invention relates to lactobacillus rhamnosus CBBM005 and application thereof in products for balancing intestinal flora, improving immunity and improving oral cavity, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CBBM005 is separated from human intestinal secretion, the lactobacillus rhamnosus CBBM005 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, and the preservation number is CGMCC NO.33904. The lactobacillus rhamnosus CBBM005 has the characteristics of balancing intestinal flora, improving immunity and improving oral cavity.

The invention relates to the technical field of land improvement, in particular to an alginic acid type multifunctional long-acting soil conditioner and a preparation method and application of the alginic acid type multifunctional long-acting soil conditioner. The core particle layer comprises an organic material, nano silicon, calcium magnesium polyphosphate, magnesium hydride, ammonium borate, rhamnose and an adhesive, and the slow release layer comprises clay minerals and alginate; the mass ratio of the clay mineral to the alginate to the organic material to the calcium magnesium polyphosphate to the nano silicon to the magnesium hydride to the ammonium borate to the rhamnose to the binder is controlled within a certain range. The soil conditioner provided by the invention is good in slow release performance, can release effective components durably and slowly, and has multiple effects of improving soil quality, providing nutrition, promoting crop growth, improving resistance and the like; the problems of soil acidification, heavy metal pollution, micro-plastic pollution, pesticide pollution, antibiotic pollution and the like in agricultural production can be effectively solved.

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.

The present invention provides a Lacticaseibacillus rhamnosus UP180, and its preservation number is CGMCC NO.32109. The present invention also provides a fermentation product obtained by fermenting astragalus extract by the Lacticaseibacillus rhamnosus UP180. The present invention also provides a probiotic preparation, including the Lacticaseibacillus rhamnosus UP180, which helps to promote growth and development. The present invention also provides a preparation method of the probiotic preparation, including the steps of fermenting and culturing the probiotics to obtain bacterial mud, and freeze-drying the bacterial mud after mixing it with a freeze-drying protective agent. It is convenient for subsequent industrial applications.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention relates to the technical field of microorganisms, in particular to application of lactobacillus rhamnosus KF7 in improving intestinal barrier injury and regulating intestinal flora and functional food containing the lactobacillus rhamnosus KF7. The invention provides application of lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The preservation number of the lactobacillus rhamnosus KF7 is CGMCC (China General Microbiological Culture Collection Center) NO.6430. The invention further provides application of the lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The invention discloses the novel application of the caseus rhamnosus KF7 in the aspects of improving the normal intestinal epithelial barrier function, protecting the normal intestinal epithelial barrier from lipopolysaccharide induced barrier injury, recovering animal intestinal barrier injury caused by rhythm disorder, regulating intestinal flora disorder and improving growth, development and metabolic states for the first time. The method can be used for producing functional food products such as fermented milk, lactic acid bacteria beverages, probiotic powder, viable bacteria water, milk powder and cheese.

The invention provides homogenized pitaya polysaccharide as well as a preparation method and application thereof, and belongs to the technical field of polysaccharide extraction and purification. The homogenized pitaya polysaccharide is a polysaccharide of which the monosaccharide is composed of mannose, glucosamine hydrochloride, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, the relative molecular weight is 8.08 * 10 < 4 > Da, and the corresponding molar ratio is (0.181): (0.250): (16.544): (12.762): (3.793): (0.739): (51.014): (14.716). The invention further provides a preparation method of the homogenized pitaya polysaccharide and application of the homogenized pitaya polysaccharide in preparation of lipid-lowering and sugar-lowering drugs. The homogenized pitaya polysaccharide disclosed by the invention has an obvious lipid-lowering and blood-glucose-reducing effect, is from a natural product, so that the homogenized pitaya polysaccharide has no toxic or side effect and can be used for preparing lipid-lowering and blood-glucose-reducing medicines.

The invention discloses application of a ganoderma lucidum strain SS30 in preparation of a product for treating cancers, and belongs to the technical field of biology. The invention provides ganoderma lucidum strain SS30 mycelium polysaccharide. The ganoderma lucidum strain SS30 mycelium polysaccharide is prepared from glucose, galactose, mannose, fucose, xylose, arabinose, rhamnose, glucuronic acid, glucosamine, ribose and lacturonic acid. The polysaccharide has a remarkable effect of inhibiting transplantable pancreatic cancer and primary colorectal cancer, can achieve the effect of treating cancer by improving the immune function and reducing the oxidation product generation level, provides a new material for development and utilization of lucid ganoderma and products thereof, and has a wide application prospect. And a research basis is provided for research and development of cancer-related drugs and research of a cancer treatment mechanism.

The invention relates to the field of establishment of fingerprints of traditional Chinese medicinal materials, in particular to an establishment method and application of a salvia miltiorrhiza polysaccharide HPLC (High Performance Liquid Chromatography) fingerprint. The establishment method comprises the following steps: preparation of a test solution: taking a salvia miltiorrhiza polysaccharide hydrolysis solution, carrying out derivatization in a reaction bottle, and passing through a 0.1-0.3 [mu] m microporous filter membrane; preparing a reference substance solution, namely weighing mannose, ribose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose reference substances, and preparing into a mixed reference substance solution; performing HPLC (high performance liquid chromatography) determination; and establishing the salvia miltiorrhiza polysaccharide HPLC fingerprint spectrum. According to the method, the difference of monosaccharide composition and content in salvia miltiorrhiza medicinal materials from different producing areas and the spectrum-effect relationship between antioxidant activity and anticoagulant activity are clarified, and a certain reference basis is provided for quality control and evaluation of the salvia miltiorrhiza medicinal materials from the aspect of polysaccharide.

The invention discloses application of lactobacillus rhamnosus HPT112 in preparation of a medicine for preventing and / or treating hyperuricemia, and belongs to the field of microorganisms, the lactobacillus rhamnosus HPT112 is preserved in the China Center for Type Culture Collection on November 20, 2023, and the preservation number is CCTCC NO: M20232273. Tests prove that the lactobacillus rhamnosus HPT112 has the function of regulating bile acid metabolism, so that the uric acid reducing effect is achieved, and the uric acid reducing effect equivalent to or even better than that of an existing hyperuricemia medicine can be achieved. Compared with existing hyperuricemia drugs, the lactobacillus rhamnosus HPT112 has the advantages that toxic and side effects are low, safety is high, a brand-new drug for preventing and / or treating hyperuricemia can be developed by the aid of the lactobacillus rhamnosus HPT112, and accordingly inflammatory reaction caused by hyperuricemia can be prevented and / or treated.

The application provides a lactobacillus rhamnosus GS044 and a lyophilized powder and a probiotic of the lactobacillus rhamnosus GS044 in application to promoting growth and development and improving immunity, and belongs to the technical field of microorganisms.The application provides a lactobacillus rhamnosus GS044 with a preservation number of CGMCC No.33713.The application further provides a method for preparing gamma-aminobutyric acid by using the lactobacillus rhamnosus GS044, and a lyophilized powder prepared by using the lactobacillus rhamnosus GS044, a probiotic and application of the lyophilized powder and the probiotic.The lyophilized powder and the probiotic prepared by the application can effectively promote growth and development and improve immunity.

The invention discloses a composition for treating insomnia. Comprising probiotic compounds: lactobacillus plantarum, bifidobacterium lactis, lactobacillus crispatus, lactobacillus acidophilus, lactobacillus rhamnosus, bifidobacterium bifidum, lactobacillus reuteri, lactobacillus casei, lactobacillus bulgaricus, lactobacillus fermentum, lactobacillus gasseri, lactococcus lactis, bifidobacterium longum, lactobacillus salivarius, bifidobacterium breve, streptococcus thermophilus and lactobacillus paracasei; lactobacillus helveticus; and traditional Chinese medicine components and prebiotics. Probiotics are matched with traditional Chinese medicines with homology of medicine and food, and corresponding prebiotics are supplemented, so that the balance of intestinal flora can be adjusted and information transmission between intestines and cranial nerves can be promoted through the synergistic effect of the probiotics and the corresponding prebiotics, and then gastrointestinal inflammation, ulcer, helicobacter pylori infection, constipation and insomnia are treated or improved; and treating or improving spleen and stomach disharmony, liver qi stagnation, excessive heart fire, fire excess from yin deficiency, heart-kidney disharmony caused by emotion, pressure, diseases and the like, and insomnia caused by the symptoms.

The invention belongs to the technical field of microbial fermentation, and particularly relates to pseudomonas aeruginosa and application thereof. According to the specific technical scheme, the pseudomonas aeruginosa HY-8 is preserved in the Guangdong Microbial Culture Collection Center on October 24, 2024, and the preservation number of the pseudomonas aeruginosa HY-8 is GDMCC (China General Microbiological Culture Collection Center) NO: 65339. The invention provides a strain of pseudomonas aeruginosa which can tolerate high-concentration ethanol and can produce rhamnolipid at high yield. The pseudomonas aeruginosa is used for producing the rhamnolipid through fermentation, and ethanol is added in the fermentation process, so that the problem that a large amount of foam is generated in the fermentation process can be effectively solved, the normal growth of the pseudomonas aeruginosa cannot be influenced, and the continuity and stability of the rhamnolipid produced through fermentation can be ensured, thereby greatly improving the yield of the rhamnolipid produced through fermentation.

The application discloses a kind of traditional Chinese medicine rose flower fermentation method and fermentation composition, it is related to fermentation technical field.The traditional Chinese medicine rose flower fermentation method includes: traditional Chinese medicine rose flower is crushed, mixed with water, and after sterilization, fermentation base material is obtained, yeast peptone solution is added, as blank fermentation pre-liquid;Activated rhamnolipid lactose casein bacillus liquid is inoculated in blank fermentation pre-liquid, and fermentation is carried out.The traditional Chinese medicine rose flower fermentation method provided by the application uses traditional Chinese medicine rose flower as raw material, and utilizes activated rhamnolipid lactose casein bacillus liquid to ferment, without adding exogenous sugar in the fermentation process, but before fermentation, yeast peptone is added first, the addition of yeast peptone can supplement nitrogen source for the fermentation process of subsequent activated rhamnolipid lactose casein bacillus liquid, so that the nutrient content of fermented rose flower is more, and component conversion is more thorough.It is favorable to improve the DPPH free radical scavenging rate, total phenol content and antioxidant property of fermentation composition.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention relates to gardenia polysaccharide as well as a preparation method and application thereof. The gardenia polysaccharide comprises the following monosaccharide units: rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, or mainly comprises rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose; the molar ratio of rhamnose to glucuronic acid to galacturonic acid to glucose to galactose to arabinose in the gardenia polysaccharide is (3-15): (1-8): (4-18): (1-6): (15-35): (25-70). According to the gardenia polysaccharide, FFA induced mouse primary parenchymal hepatic cell lipid accumulation can be reduced, no obvious cytotoxic effect exists, CDAHFD diet induced hepatic fibrosis can be reduced, and the gardenia polysaccharide has a good effect of preventing and / or treating non-alcoholic steatohepatitis.

The invention discloses a strain of lactobacillus plantarum, which is named as L.plantarum ZW1, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) 26685. The lactobacillus plantarum provided by the invention is a lactic acid bacterium with relatively strong broad-spectrum inhibition capability, and after the interference of organic acid and hydrogen peroxide is eliminated and protease treatment verification is carried out, the strain is determined to have relatively strong bacteriocin production capability. Probiotic performance evaluation shows that the strain has good digestive tract fluid tolerance, and the L.plantarum CGMCC26685 has good intestinal tract probiotic characteristics, can significantly enrich mouse intestinal flora in an in-vitro intestinal flora fermentation model, increase the relative abundance of the phylum of thick-walled bacteria, reduce the relative abundance of the phylum of proteobacteria, proteusbacillus and shigella, and improve the intestinal tract fluid resistance of mice. The number of flora OTU is obviously higher than that of lactobacillus rhamnosus LGG and lactobacillus plantarum L.plantarum PL4 group which does not produce bacteriocin, and the Chao1 index, the Shannon index and the Simpson index are obviously improved compared with those of a control group. It is shown that the L.plantarum CGMCC26685 has good intestinal tract beneficial activity, and has the potential of further performance excavation and application expansion.

The invention relates to the technical field of food processing, in particular to cubilose nourishing, conditioning and blood sugar reducing health-care food and a preparation process thereof. The cubilose enters the palace from the clear generation, becomes a defending tonic, is a medicinal and edible tonic, and has the beauty of a rare famous drug and an oriental treasure. The cubilose is rich in sialic acid, protein, amino acid and other bioactive substances, so that the cubilose has a nourishing effect and has certain health-care and conditioning effects on the lung, the kidney and the stomach. According to the preparation method, the cherry and the honeysuckle are subjected to synergistic fermentation through the rhamnolactobacilli and the saccharomycetes, so that the performance is improved, and the prepared cubilose health-care food has the effect of reducing blood sugar.

The invention relates to the technical field of biology, and provides a probiotic composition for relieving sarcopenia obesity and application of the probiotic composition. The composition comprises at least two of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Wherein the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.25839; the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.26968; the preservation number of the animal bifidobacterium subsp. Lactis is CGMCC (China General Microbiological Culture Collection Center) No. 27998. The composition disclosed by the invention can be used for increasing the muscle content of an organism, improving the muscle tissue form, increasing adenosine triphosphate and inhibiting abnormal increase of body weight, so that the composition can be used for effectively preventing and treating sarcopenia obesity.

The invention provides marine-derived lactobacillus rhamnosus S400M01 and application thereof, and relates to the technical field of heavy metal adsorption and removal, the marine-derived lactobacillus rhamnosus S400M01 is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on November 28, 2022, the preservation address is Guangzhou, and the number is GDMCCNO: 63001. The strain can tolerate cadmium chloride concentration up to 1000 mg / L, can tolerate lead concentration up to 800 mg / L, can adsorb and remove heavy metals cadmium and lead in squid viscera, and reduces accumulation of cadmium and lead in viscera of live crucian in a heavy metal polluted water body.

The invention discloses an application of rhamnolipid in improving transparency and a shampoo, particularly discloses an application of a rhamnolipid composition in improving transparency of a daily chemical product with a cationic conditioner, and discloses the shampoo which comprises a surfactant and the cationic conditioner, the surface active agent comprises rhamnolipid and a group consisting of other surface active agents except the rhamnolipid; the mass ratio of the rhamnolipid in the shampoo is more than 0.5%, and the mass ratio of the cationic conditioner in the shampoo is more than 0.01%. When the rhamnolipid is applied to the daily chemical product with the cationic conditioner, excellent transparency is shown, the transparency defect caused by the fact that a surfactant surfactant formula purely using a petrochemical source is used in cooperation with the cationic conditioner is overcome, and meanwhile the defect of the rhamnolipid in the aspect of foam is avoided; and the user experience of consumers is better.

The invention discloses application of lactobacillus rhamnosus in preparation of a preparation for relieving allergic rhinitis. The invention provides application of the lactobacillus rhamnosus OF44-15Ph10T or a composition containing the lactobacillus rhamnosus OF44-15Ph10T in preparation of a product with at least one of the following functions: preventing and / or treating allergic rhinitis; the symptoms of allergic rhinitis are improved or relieved; the nasal mucosa injury caused by allergic rhinitis is repaired; intestinal pathogens are inhibited; the intestinal flora balance is regulated; the lactobacillus rhamnosus OF44-15Ph10T provided by the invention provides a new direction for treating allergic rhinitis, can be applied to the fields of food, health care products and medicines, and has a wide industrial prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to a postbiotic hydrogel for relieving alcoholic gastric ulcer as well as a preparation method and application thereof. The metagen hydrogel for relieving the alcoholic gastric ulcer, provided by the invention, is mainly prepared from metagen of rhamnobacter and modified lactoferrin; the lactobacillus rhamnosus is lactobacillus rhamnosus JM023. Tests prove that when the postbiotic hydrogel is applied to an alcoholic gastric ulcer rat model, the occurrence of gastric ulcer can be inhibited by inhibiting oxidative stress and inflammatory response and improving protection factor secretion; and the alcoholic gastric ulcer is relieved by regulating and controlling the expression of oxidation, inflammation, cell apoptosis and tissue repair related metabolic pathways and regulating gastrointestinal flora. The metagen hydrogel disclosed by the invention has the effect of effectively relieving gastric ulcer symptoms caused by alcohol, and is suitable for being developed and applied as a medicine or a health-care product for relieving alcoholic gastric ulcer.

The invention provides a Burkholderia thailantensis DIS2 bacterium, a Burkholderia thailantensis DIS2.1 bacterium, a bacterium with all recognition characteristics of the Burkholderia thailantensis DIS2 bacterium and the Burkholderia thailantensis DIS2.1 bacterium, and a mutant of the Burkholderia thailantensis DIS2 bacterium and the Burkholderia thailantensis DIS2.1 bacterium. The invention also provides a Starmerella bombicola DIS4 yeast, a yeast with all recognition characteristics of the Starmerella bombicola DIS4 yeast, and a mutant of the Starmerella bombicola DIS4 yeast. Also provided are methods for producing rhamnolipids and methods for producing sophorolipids. In order to produce rhamnolipids, raw materials comprising waste carbon sources and fried edible oil are fermented with Burkholderia Thailand, mutants or variants thereof. Similarly, in order to produce sophorolipids, a raw material comprising a waste carbon source and a deep-fried edible oil is fermented with Starmomyces sp., a mutant or a variant thereof.

The application provides a Huangdache oligosaccharide with GLP-1 agonist activity and application thereof, and belongs to the technical field of medicines. 3 The oligosaccharide component ELYP-3 has a molecular weight of 3.2*10 3 Da, and the molar ratio of monosaccharides is rhamnose:galacturonic acid:glucose:galactose:arabinose = 1:32.42:45.37:9.11:6.54. The Huangdache oligosaccharide fragment obtained by glycosidase degradation has significant hypoglycemic and weight loss activities, the preparation process is simple, specific and green, and provides scientific basis and theoretical support for the development of natural GLP-1 agonists. Meanwhile, the functional oligosaccharide provides a wide application prospect for the development of medicines with blood glucose regulation.

The invention relates to the field of acute lung injury caused by sepsis, in particular to application of lactobacillus rhamnosus exosome in preparation of medicine for treating and / or preventing acute lung injury caused by sepsis of subjects, and the acute lung injury caused by sepsis is acute complication of sepsis. The sepsis is caused by bacterial infection, and the particle size of the lactobacillus rhamnosus exosome ranges from 50 nm to 120 nm. The lactobacillus rhamnosus exosome provided by the invention can prevent and / or timely and effectively prevent the development of the disease course of a subject at the initial stage of sepsis acute lung injury, and finally, the treatment success rate of the subject is increased, and the prognosis of the subject is improved.